220 related articles for article (PubMed ID: 12473587)
1. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
[TBL] [Abstract][Full Text] [Related]
2. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
Silva JM; Dominguez G; Garcia JM; Gonzalez R; Villanueva MJ; Navarro F; Provencio M; San Martin S; España P; Bonilla F
Cancer Res; 1999 Jul; 59(13):3251-6. PubMed ID: 10397273
[TBL] [Abstract][Full Text] [Related]
3. Extracellular tumor DNA in plasma and overall survival in breast cancer patients.
Garcia JM; Garcia V; Silva J; Peña C; Dominguez G; Sanchez A; Sanfrutos L; Provencio M; Millan I; Chaparro D; España P; Bonilla F
Genes Chromosomes Cancer; 2006 Jul; 45(7):692-701. PubMed ID: 16607614
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
6. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
7. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.
Domínguez G; Carballido J; Silva J; Silva JM; García JM; Menéndez J; Provencio M; España P; Bonilla F
Clin Cancer Res; 2002 Apr; 8(4):980-5. PubMed ID: 11948103
[TBL] [Abstract][Full Text] [Related]
8. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
Schwarzenbach H; Müller V; Stahmann N; Pantel K
Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
[TBL] [Abstract][Full Text] [Related]
9. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
10. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.
Chen X; Bonnefoi H; Diebold-Berger S; Lyautey J; Lederrey C; Faltin-Traub E; Stroun M; Anker P
Clin Cancer Res; 1999 Sep; 5(9):2297-303. PubMed ID: 10499596
[TBL] [Abstract][Full Text] [Related]
11. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
12. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
[TBL] [Abstract][Full Text] [Related]
13. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
[TBL] [Abstract][Full Text] [Related]
14. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
18. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
[TBL] [Abstract][Full Text] [Related]
19. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]